Longevity Medicine Hong Kong: What's Available & How It Works (2026)
Longevity Medicine Is No Longer a Fringe Interest — It Has Moved into Clinical Practice
Longevity medicine — the clinical discipline focused on extending healthspan (years of healthy, functional life) rather than simply treating disease — has undergone a significant shift in the past decade. What was once the domain of Silicon Valley biohackers and academic laboratories has moved into mainstream clinical practice, driven by a convergence of scientific advances, patient demand, and the availability of interventions with meaningful evidence bases.
The science is being done at serious institutions. Research programmes at Harvard, Stanford, MIT, the Salk Institute, and the Buck Institute for Research on Ageing have identified specific biological mechanisms of ageing — NAD+ depletion, cellular senescence, telomere erosion, mitochondrial dysfunction, chronic inflammation — and shown in animal models (and increasingly in early human trials) that these mechanisms are modifiable.
In Hong Kong, a growing number of clinics offer treatments positioned under the longevity banner. The quality and clinical basis of these offerings varies considerably. This guide explains what longevity medicine actually is, what the evidence-based interventions look like, what's currently available in Hong Kong, and how to build a programme that makes rational sense for your biology and goals.
What Is Longevity Medicine?
Longevity medicine is distinct from standard healthcare in its framing: rather than waiting for disease to occur and treating it, longevity medicine aims to modify the underlying biological processes that make disease more likely as we age, and to maintain the functional capacity — physical, cognitive, metabolic, hormonal — that declines progressively from middle age onward.
The field is organised around what researchers call the "hallmarks of ageing" — biological processes identified as central to why organisms age and become more vulnerable to disease over time. These include:
Genomic instability (accumulation of DNA damage)
Telomere attrition (shortening of the protective caps on chromosomes)
Epigenetic alterations (changes in gene expression patterns)
Loss of proteostasis (accumulation of damaged proteins)
Deregulated nutrient sensing (impaired metabolic signalling)
Mitochondrial dysfunction (declining cellular energy production)
Cellular senescence (accumulation of non-dividing, inflammatory "zombie" cells)
Stem cell exhaustion (reduced regenerative capacity)
Altered intercellular communication (dysregulated signalling between cells)
Longevity interventions aim to slow, halt, or partially reverse one or more of these processes. The available tools range from pharmaceutical drugs (rapamycin, metformin — used off-label) to biological therapies (NAD+, peptides) to lifestyle medicine (exercise, nutrition, sleep) to emerging approaches (senolytics, gene therapy) still largely in the research phase.
Longevity Interventions Available in Hong Kong in 2026
NAD+ IV therapy — cellular energy and repair
NAD+ supplementation addresses one of the best-characterised hallmarks of ageing: the progressive decline in NAD+ levels that impairs mitochondrial function, DNA repair (via PARP enzymes), and cellular stress responses (via sirtuins). IV delivery achieves bioavailability and plasma concentrations that oral precursors cannot match. The evidence base, while still developing in human RCT form, is mechanistically strong and clinically supported by animal research and growing human data.
At REVIV, NAD+ IV is used as a cornerstone of longevity programmes — both as a standalone treatment and in combination with other interventions.
GLP-1 therapy — metabolic longevity
Metabolic dysfunction is a primary driver of accelerated biological ageing. Insulin resistance, visceral adiposity, chronic low-grade inflammation, and elevated blood sugar all accelerate multiple hallmarks of ageing. GLP-1 receptor agonists (Ozempic, Mounjaro) address these directly — producing substantial weight reduction, improved insulin sensitivity, reduced inflammatory markers, and (in the SELECT trial) a 20% reduction in major cardiovascular events in patients with cardiovascular disease.
For patients with excess weight or metabolic dysfunction, GLP-1 therapy is one of the most impactful longevity interventions available — not because it directly targets ageing biology, but because it removes one of the most significant accelerants of biological ageing.
Peptide therapy — hormonal restoration and recovery
Growth hormone decline is a well-established aspect of ageing, contributing to body composition changes, reduced physical resilience, slower recovery, and changes in sleep architecture. Growth hormone-releasing peptides (CJC-1295, ipamorelin) stimulate the body's own GH production without direct exogenous hormone administration, partially restoring growth hormone signalling with a more physiological mechanism than direct GH replacement.
Other peptides used in longevity contexts include epithalon (associated with telomere protection and circadian regulation in animal research) and BPC-157 (systemic anti-inflammation and tissue repair).
IV nutritional therapy — supporting cellular function
IV glutathione addresses a specific longevity-relevant deficit: glutathione is the body's primary intracellular antioxidant, and its levels decline with age and chronic oxidative stress. Intravenous delivery achieves intracellular concentrations relevant to cellular protection. High-dose vitamin C IV supports collagen synthesis, immune function, and antioxidant defence. Bespoke IV vitamin and mineral formulations address nutrient deficiencies that become increasingly common with age.
Comprehensive biomarker monitoring
A longevity programme without monitoring is not a programme — it is a series of treatments with no feedback loop. Relevant monitoring includes not just standard annual blood panels but longitudinal tracking of metabolic markers (fasting insulin, HbA1c, triglycerides, ApoB), inflammatory markers (hsCRP, IL-6), hormonal markers (IGF-1, sex hormones, thyroid), and in more advanced programmes, epigenetic age testing (biological age measured through DNA methylation patterns).
What Is Not (Yet) Widely Available in Clinical Practice
For context, some interventions discussed extensively in longevity science are not yet established in routine clinical practice in Hong Kong:
Rapamycin: An mTOR inhibitor with strong longevity evidence in animal models, used off-label by some longevity physicians globally. Not routinely available in Hong Kong's clinical wellness market.
Senolytics: Drugs that selectively clear senescent ("zombie") cells. Dasatinib/quercetin combinations are in human trials. Not yet standard clinical practice.
Gene and stem cell therapies: Significant research interest, active in early human trials. Not yet widely available outside research settings.
Being clear about what is established practice versus what is research-phase is part of what distinguishes a credible clinical longevity programme from one that overpromises.
How to Think About Building a Longevity Programme
A rational longevity programme starts with a baseline assessment of where you are biologically — not where you feel you are or where you think you should be. Blood work and clinical assessment reveal metabolic health, inflammatory status, hormonal balance, and nutritional state. This forms the foundation for prioritising interventions.
The interventions that produce the highest impact are usually:
Foundational lifestyle: Sleep quality, resistance exercise (the most evidence-backed longevity intervention), dietary protein and nutrition, stress management. Without these, clinical interventions produce fraction of their potential effect.
Metabolic optimisation: If insulin resistance, excess visceral fat, or blood sugar dysregulation is present, addressing it (through GLP-1 therapy, dietary change, or both) has outsized downstream impact on multiple hallmarks of ageing.
Cellular support: NAD+ IV, glutathione, and IV nutritional therapy support cellular function and resilience directly. Most relevant from 40 onwards.
Hormonal and recovery support: Peptide therapy, and where appropriate, hormone optimisation, support the physical dimensions of healthy ageing — muscle maintenance, fat metabolism, sleep quality.
What Longevity Medicine Costs in Hong Kong
As a general guide:
Initial consultation and comprehensive blood panel: HK$2,000–4,000
NAD+ IV therapy (single session): HK$1,800–3,500 depending on dose
Monthly IV programme: HK$3,000–8,000 depending on protocol
GLP-1 programme (medication + monitoring): HK$3,000–6,000/month
Peptide protocol: HK$2,000–4,000 for a full cycle including training
Most patients build programmes that combine several modalities — the consultation structures what makes sense for each individual and what the realistic budget allocation is.
Frequently Asked Questions
Is longevity medicine evidence-based?
Partially. Some interventions have strong evidence from human trials (GLP-1 medications, specific vitamins and minerals IV). Others have compelling mechanistic rationale and animal evidence but limited human RCT data (NAD+ IV, many peptides). A credible longevity programme is transparent about which category each intervention falls into, rather than presenting everything as established fact.
How is longevity medicine different from anti-ageing treatments?
The terms overlap considerably. "Anti-ageing" sometimes refers to cosmetic treatments (Botox, fillers) and sometimes to clinical interventions targeting biological ageing. "Longevity medicine" more consistently refers to clinical approaches targeting healthspan and biological ageing mechanisms. At REVIV, the focus is on biological — not cosmetic — approaches.
What results can I realistically expect?
This depends heavily on baseline health, programme consistency, and lifestyle factors. Patients typically report improved energy, better sleep, improved body composition, and enhanced recovery. Reduction of longer-term biological age markers takes time to assess. Longevity medicine is a cumulative, long-term practice rather than a quick result — results compound over months and years rather than appearing in weeks.
Do I need to commit to a long programme?
An initial evaluation and starting point can be structured without committing to a multi-year programme. However, the clearest benefit from most longevity interventions comes from consistent, monitored application over months. A single NAD+ IV is useful for energy; a regular programme produces the sustained NAD+ restoration that may influence longer-term cellular function.
Start a Longevity Programme at REVIV Hong Kong
REVIV's longevity approach starts with understanding your biology and building a programme that makes rational sense for your goals and health profile. The clinical team brings together GLP-1 medicine, IV therapy, and peptide protocols — the full toolkit available in Hong Kong for longevity-focused clinical work.
Location: 1st Floor, The Plaza, 21 D'Aguilar Street, Central, Hong Kong
Opening hours: Monday to Sunday, 10:00 AM – 7:00 PM
WhatsApp: +852 9867 9183
Sources
López-Otín C et al. The Hallmarks of Aging. Cell, 2013.
Verdin E. NAD+ in Aging, Metabolism, and Neurodegeneration.Science, 2015.
Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 2018.
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 2023.
Yoshino M et al. Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women.Science, 2021.
The material on this page is provided for informational purposes only and is not medical advice. Always consult your doctor before beginning any therapy programme. All therapies are subject to medical screening and doctor consultation to approve responsible treatment.
